Considering the current observation in cervical cancer cells regarding the association between DAPK levels and the response to topotecan, the reactivation of DAPK1 in cervical tumors that do not express DAPK by demethylating agents may re-sensitize cervical cancer to topotecan and other chemotherapeutics. The gene discussed is DAPK1; the disease is cervical cancer.